Prometheus Laboratories Showcases Drug Clearance as a Foundation for Precision Guided Biologic Dosing in IBD at DDW 2026

Real‑world and prospective data demonstrate the role of clearance‑informed, precision‑guided dosing in supporting individualized treatment decisions and durable disease control SAN DIEGO, CA / ACCESS ...

Prometheus Signals Near-Term Development of Next-Generation Noninvasive Test for MASH Patients at DDW 2026

Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal Assessment as MASH Therapies Expand. SAN DIEGO, CA ...
Reuters

Prometheus Labs to acquire Glaxo bowel drug

NEW YORK, Nov 7 (Reuters) - Privately held Prometheus Laboratories Inc said on Wednesday it has agreed to acquire exclusive U.S. rights to GlaxoSmithKline's irritable bowel syndrome drug Lotronex.

Prometheus Laboratories: Prometheus Signals Near-Term Development of Next-Generation Noninvasive Test for MASH Patients at DDW 2026

Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal Assessment as MASH Therapies Expand SAN DIEGO, CA / ACCESS Newswire / Ma ...